September 28, 2026, Wetzlar, Germany – Leica Microsystems, a Danaher company and a leading provider of microscopy and scientific solutions, today announced the launch of Autiva Spatial Phenotyper, a new spatial biology imaging platform, to help researchers generate results more quickly and consistently. It combines automated staining, multiplex imaging, reagents and AI-powered analysis in a unified workflow designed for spatial biology research.
“By combining our imaging excellence with intelligent automation, an expanding reagent ecosystem, and AI-enabled analysis, Autiva Spatial Phenotyper helps researchers transform complex tissue biology into meaningful spatial insights,” said Nicolas Pierre, Vice President and General Manager Life Science and Applied Solutions at Leica Microsystems. “The platform enables laboratories to characterize tissue phenotypes with greater efficiency and consistency, accelerating biomarker discovery, translational research, and the development of next-generation therapies.”
Autiva Spatial Phenotyper is designed for “walk-away” operation powered by precision microfluidic controls, enabling accelerated insights with up to 3x higher throughput and minimal manual interaction. For biopharma users looking for a high degree of automation, it can run overnight 24-plex experiments while processing up to four slides in parallel. Once the samples and reagents are loaded, the system executes automated cyclic staining, de-staining and imaging, with the ability to replenish reagents mid-run to support large-scale, multi-day experiments.
Purpose-built for multiplex spatial biology, Autiva Spatial Phenotyper captures high-quality images that help researchers identify cellular phenotypes and uncover meaningful tissue interactions within complex tissue samples to accelerate the discovery of next-generation biomarkers and therapies.
Its configurable imaging platform supports evolving research needs. Together with the expanding ATTOAuriga spatial reagent ecosystem and adaptable Aivia software analysis workflows, it allows laboratories to tailor experiments to scientific objectives. Plus, using automated cell segmentation and phenotype classification capabilities of Aivia software, researchers can explore spatial relationships within tissues, turning complex multiplexed images into quantitative results.
Autiva Spatial Phenotyper is available through Leica Microsystems and authorized partners. For more information, please visit https://www.leica-microsystems.com/products/light-microscopes/p/autiva/
About Leica Microsystems
Leica Microsystems, a Danaher company, supports the generation of insight from complex imaging data, enabling faster, informed decisions across life science, medical, and industrial applications. Guided by its purpose to reveal what is invisible, the company partners closely with customers to translate this insight into meaningful outcomes and contribute to a better and healthier world. The Leica Microsystems portfolio spans workflows from sample preparation to AI-enabled analysis. It builds on more than 175 years of expertise in microscopy, combining customer focus, continuous improvement, and innovation. As part of the Danaher ecosystem, Leica Microsystems connects imaging with complementary technologies and expertise to address broader scientific and clinical needs. Headquartered in Wetzlar, Germany, the company operates six major manufacturing and development sites and serves customers in more than 100 countries. Explore more at: https://www.leica-microsystems.com.
About Danaher
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at https://www.danaher.com.
